Cross-Sector entity
Every one of those 1 sits in a single category, pharma. Epigenetic Clock is most often covered alongside COSMOS Trial, which appears in 1 of these 1 story. Epigenetic Clock appears in 1 tracked Cross-Sector story from March 9, 2026.
1 verified story tracked
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Epigenetic Clock is most often covered alongside COSMOS Trial, which appears in 1 of these 1 story. Epigenetic Clock appears in 1 tracked Cross-Sector story from March 9, 2026. The tracked stories average 57 original sources each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Epigenetic Clock. Shared-story counts are live from our verified record — not editorial picks.
Biological Aging Data
New analysis links multivitamin use to slower epigenetic aging markers.
COSMOS-Clinic Update
In-person clinical assessments reinforce cognitive aging slowing by 3 years.
COSMOS-Web Study
Large-scale web-based study confirms memory benefits of daily supplements.
COSMOS-Mind Results
Initial findings show multivitamins improve cognition in older adults.
A significant new clinical study indicates that daily multivitamin supplementation may slow biological aging in older adults by approximately two years. The findings suggest that consistent micronutrient intake supports cellular health and mitigates the epigenetic markers associated with age-related decline.
